Analysts at Bernstein have increased the stock price target for Edwards Lifesciences, following the medical device company's better-than-expected second-quarter results.
Edwards Lifesciences reported a second-quarter earnings beat, exceeding analysts' projections.
The strong performance led Bernstein to revise its assessment upward, raising the price target on Edwards Lifesciences shares.
Edwards Lifesciences is 'The Cleanest Large-Cap Medtech Story'.